EGFR and non-small cell lung carcinoma: Consistently, c-Myc levels are elevated in the majority of EGFR-mutant NSCLC tissues from patients who relapsed on EGFR-TKI treatment compared with the corresponding baseline c-Myc levels prior to treatment [70].